CN113302185A - 苯并呋喃-6-甲酰胺衍生物、其制备方法和药学上的应用 - Google Patents

苯并呋喃-6-甲酰胺衍生物、其制备方法和药学上的应用 Download PDF

Info

Publication number
CN113302185A
CN113302185A CN201980088575.4A CN201980088575A CN113302185A CN 113302185 A CN113302185 A CN 113302185A CN 201980088575 A CN201980088575 A CN 201980088575A CN 113302185 A CN113302185 A CN 113302185A
Authority
CN
China
Prior art keywords
radical
deuterium
substituted
membered
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201980088575.4A
Other languages
English (en)
Other versions
CN113302185B (zh
Inventor
寻国良
赵保卫
喻红平
陈椎
徐耀昌
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbisko Therapeutics Co Ltd
Original Assignee
Abbisko Therapeutics Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbisko Therapeutics Co Ltd filed Critical Abbisko Therapeutics Co Ltd
Publication of CN113302185A publication Critical patent/CN113302185A/zh
Application granted granted Critical
Publication of CN113302185B publication Critical patent/CN113302185B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80Radicals substituted by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

一种具有式(I)结构的苯并呋喃‑6‑甲酰胺衍生物、其制备方法和药学上的应用,各取代基的定义如说明书和权利要求书所述。本发明系列化合物可广泛应用于制备治疗一种或多种肿瘤、癌症、代谢性疾病、自身免疫性疾病或紊乱的药物,有望开发成新一代RORγt激动剂药物。

Description

PCT国内申请,说明书已公开。

Claims (19)

  1. PCT国内申请,权利要求书已公开。
CN201980088575.4A 2019-04-29 2019-09-16 苯并呋喃-6-甲酰胺衍生物、其制备方法和药学上的应用 Active CN113302185B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2019103561744 2019-04-29
CN201910356174 2019-04-29
PCT/CN2019/105994 WO2020220562A1 (zh) 2019-04-29 2019-09-16 苯并呋喃-6-甲酰胺衍生物、其制备方法和药学上的应用

Publications (2)

Publication Number Publication Date
CN113302185A true CN113302185A (zh) 2021-08-24
CN113302185B CN113302185B (zh) 2024-04-09

Family

ID=73029663

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980088575.4A Active CN113302185B (zh) 2019-04-29 2019-09-16 苯并呋喃-6-甲酰胺衍生物、其制备方法和药学上的应用

Country Status (2)

Country Link
CN (1) CN113302185B (zh)
WO (1) WO2020220562A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016057931A1 (en) 2014-10-10 2016-04-14 The Research Foundation For The State University Of New York Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104853757A (zh) * 2012-08-15 2015-08-19 默沙东公司 作为RORγT抑制剂的4-杂芳基取代的苯甲酸化合物及其用途
CN106132422A (zh) * 2014-02-27 2016-11-16 莱斯拉公司 使用视黄酸受体相关孤儿受体γ的激动剂的过继细胞疗法&相关治疗方法
CN106995416A (zh) * 2016-01-26 2017-08-01 上海翰森生物医药科技有限公司 Fxr激动剂及其制备方法和应用
CN107428742A (zh) * 2015-11-19 2017-12-01 江苏恒瑞医药股份有限公司 苯并呋喃类衍生物、其制备方法及其在医药上的应用
WO2018137655A1 (zh) * 2017-01-25 2018-08-02 江苏豪森药业集团有限公司 吡咯并吡啶类n-氧化衍生物及其制备方法和应用
WO2018233553A1 (zh) * 2017-06-19 2018-12-27 广东东阳光药业有限公司 稠合双环类化合物及其在药物中的应用
WO2019062848A1 (zh) * 2017-09-29 2019-04-04 浙江海正药业股份有限公司 N-(取代磺酰基)苯甲酰胺类衍生物及其制备方法和医药用途

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104853757A (zh) * 2012-08-15 2015-08-19 默沙东公司 作为RORγT抑制剂的4-杂芳基取代的苯甲酸化合物及其用途
CN106132422A (zh) * 2014-02-27 2016-11-16 莱斯拉公司 使用视黄酸受体相关孤儿受体γ的激动剂的过继细胞疗法&相关治疗方法
CN107428742A (zh) * 2015-11-19 2017-12-01 江苏恒瑞医药股份有限公司 苯并呋喃类衍生物、其制备方法及其在医药上的应用
CN106995416A (zh) * 2016-01-26 2017-08-01 上海翰森生物医药科技有限公司 Fxr激动剂及其制备方法和应用
CN109071470A (zh) * 2016-01-26 2018-12-21 江苏豪森药业集团有限公司 Fxr激动剂及其制备方法和应用
WO2018137655A1 (zh) * 2017-01-25 2018-08-02 江苏豪森药业集团有限公司 吡咯并吡啶类n-氧化衍生物及其制备方法和应用
WO2018233553A1 (zh) * 2017-06-19 2018-12-27 广东东阳光药业有限公司 稠合双环类化合物及其在药物中的应用
WO2019062848A1 (zh) * 2017-09-29 2019-04-04 浙江海正药业股份有限公司 N-(取代磺酰基)苯甲酰胺类衍生物及其制备方法和医药用途

Also Published As

Publication number Publication date
CN113302185B (zh) 2024-04-09
WO2020220562A1 (zh) 2020-11-05

Similar Documents

Publication Publication Date Title
CN109983007B (zh) 酰胺类衍生物抑制剂及其制备方法和应用
CN111356680A (zh) Nlrp3炎性体的选择性抑制剂
CN110461841B (zh) 一种具有csf1r抑制活性的氮杂芳基衍生物、其制备方法和应用
WO2019205983A1 (zh) 氧杂螺环类化合物及其制备方法和用途
WO2002102807A1 (fr) Nouveaux derives d'isoxazolopyridone et leur utilisation
CN115605475A (zh) 一种免疫抑制剂、其制备方法和应用
CN111343988A (zh) 作为ehmt2抑制剂的胺取代的杂环化合物及其衍生物
WO2021047547A1 (zh) 新型三环芳香杂环化合物,及其制备方法、药物组合物和应用
WO2020192650A1 (zh) 酰胺类化合物制备方法及其在医药领域的应用
WO2022268152A1 (zh) Glp-1受体激动剂及其组合物和用途
WO2017124936A1 (zh) 作为布罗莫区结构域抑制剂的咔啉衍生物
WO2021047553A1 (zh) 含三环结构的芳香杂环化合物,及其制备方法和应用
CN112601745B (zh) 一种氮杂芳基酰胺衍生物及其制备方法和应用
CN113302185A (zh) 苯并呋喃-6-甲酰胺衍生物、其制备方法和药学上的应用
WO2019144765A1 (zh) 芳香杂环取代烯烃化合物、其制备方法、药物组合物和应用
WO2022033416A1 (zh) 作为egfr抑制剂的稠环化合物及其制备方法和应用
WO2023116877A1 (zh) 作为tead抑制剂的杂环化合物
WO2023134764A1 (zh) 含吡啶多环类衍生物、其制备方法和应用
CN107428682B (zh) 酰胺类衍生物、其制备方法及其在医药上的用途
CN115724843A (zh) Sos1抑制剂、包含其的药物组合物及其用途
AU2019424628B2 (en) 1,2,3,4-tetrahydroquinoxaline derivative, preparation method therefor and application thereof
WO2020173328A1 (zh) 吡咯类衍生物及其制备方法与应用
CN109232533A (zh) 氮杂环类衍生物、其制备方法及其医药用途
WO2023165574A1 (zh) 用作tyk2抑制剂的化合物、其制备方法及其在医药上的应用
WO2020200161A1 (zh) 含吲唑基的三并环类衍生物的盐及其晶型

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant